A Pilot Study of the Bioavailability of Nasal Naloxone

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Drug Overdose
Interventions
DRUG

naloxone intranasal

If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally

DRUG

naloxone intravenous

The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position

Trial Locations (1)

Unknown

Department of circulation and medical imaging, NTNU, Trondheim

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

University of Iceland

OTHER

lead

Norwegian University of Science and Technology

OTHER

NCT01939444 - A Pilot Study of the Bioavailability of Nasal Naloxone | Biotech Hunter | Biotech Hunter